Imricor logs minimal revenue as U.S. commercial launch begins
Imricor reported negligible first-half revenue but said it had secured additional FDA clearances as it starts selling its MRI-guided cardiac ablation products in the United States.
News Archive
Every report the desk has filed, searchable by full text, topic, format, symbol and date range.
Filtering:IMR.AX
Most covered symbols